Ulocuplumab represents a exciting breakthrough in the treatment of Alpha-Gal syndrome, a growing condition triggered by tick bites. This novel molecule works by blocking the Alpha-Gal carbohydrate before it interacts with the immune response, hopefully preventing allergic manifestations. Initial clinical trials have demonstrated encouraging effects